share_log

中国生物制药:首个国产ROS1阳性非小细胞肺癌靶向药安柏尼获批上市

JRJ Finance ·  Apr 29 23:18

中国生物制药下属正大天晴药业集团申报的1类创新药富马酸安奈克替尼胶囊已经获得国家药监局上市批文,该药是首个获批用于ROS1阳性非小细胞肺癌的国产靶向药。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment